Bullish Upgrade
Craig-Hallum analyst Frank Brisebois initiated coverage of Strongbridge Biopharma with a Buy rating and $7.50 price target. While delays in Strongbridge's second Phase 3 LOGICS readout have weighed on the stock, Brisebois says he believes its positive first Phase 3 SONICS readout significantly de-risks LOGICS's outcome. He is particularly encouraged by Recorlev's effect on key secondary cardiovascular and liver-related endpoints.
thefly.com
Craig-Hallum analyst Frank Brisebois initiated coverage of Strongbridge Biopharma with a Buy rating and $7.50 price target. While delays in Strongbridge's second Phase 3 LOGICS readout have weighed on the stock, Brisebois says he believes its positive first Phase 3 SONICS readout significantly de-risks LOGICS's outcome. He is particularly encouraged by Recorlev's effect on key secondary cardiovascular and liver-related endpoints.
thefly.com